US Senators Seek 'Clarity’ On Middlemen Obstructing List Price Reductions
Letters to several pharmacy benefit managers and wholesalers request information on whether middlemen have discouraged decrease in list prices.
You may also be interested in...
Changing US drug rebating policy is like throwing an activated grenade into the middle of the American drug distribution system. Yet, increasingly it seems the US drug market is poised for a big shake up when it comes to the way pharmaceuticals manufacturers price their drugs, negotiate market access with payers, and pay back-end discounts to offset the cost of their products.
Dozen drug pricing transparency bills enacted into law over past two years impose different requirements on manufacturers, with a few honing in on PBMs; interactive graphic details these and other pharma-related laws.
Companies should introduce same drug under new NDC at lower list price to overcome difficulties of reducing list prices on existing brands, PBM says.